Deal Watch: Harbour Expands Horizons Beyond China
Antibody developer Harbour Biomed signs its first deal for rights outside China in cancer pact with Kelun. Portage buys SalvaRx to increase its immuno-oncology capabilities, while Paragon spinout Emalex will take over Psyadon’s pediatric Tourette syndrome program.
You may also be interested in...
Finance Watch: Emalex Raises $250m To Fund Phase III Tourette’s Trial
Private Company Edition: The Paragon Biosciences-founded Emalex previously raised $35m when ecopipam was in Phase II. Also, Catalio Capital launches a “special situations” fund, Zenas raises $118m to develop a pipeline of autoimmune disease treatments and Lusaris emerges with $60m.
Finance Watch: Latest Slate Of VC Mega-Deals Led By China-Based Biopharmas
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
Asia Deal Watch: Daiichi Sankyo Pays $200m To Ultragenyx For AAV Technology Access
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context